Skip to Content

Join the 'Ustekinumab' group to help and get support from people like you.

Ustekinumab News

Drug Stelara May Ease Crohn's Disease

Posted 18 Nov 2016 by Drugs.com

THURSDAY, Nov. 17, 2016 – People with moderate to severe Crohn's disease who haven't responded to other treatments may benefit from the drug ustekinumab (Stelara), a new study suggests. Stelara is a monoclonal antibody that blocks the action of the inflammatory agents interleukin-12 and interleukin-23. The drug had been approved for the treatment of psoriasis and is now approved for treating Crohn's disease as well. Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract. Crohn's usually affects the end of the small bowel and the beginning of the colon. But it may affect any part of the gastrointestinal tract, from the mouth to the anus, according to the Crohn's and Colitis Foundation of America (CCFA). Crohn's can cause diarrhea, rectal bleeding, an urgent need to move the bowels, stomach cramps, pain and constipation, the CCFA says. "Stelara is effective for ... Read more

Related support groups: Humira, Crohn's Disease, Remicade, Crohn's Disease - Maintenance, Stelara, Crohn's Disease - Acute, Cimzia, Ustekinumab

FDA Approves Stelara (ustekinumab) for Treatment of Adults with Moderately to Severely Active Crohn's Disease

Posted 27 Sep 2016 by Drugs.com

HORSHAM, Pa., Sept. 26, 2016 /PRNewswire/ – Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved Stelara (ustekinumab) for the treatment of moderately to severely active Crohn's disease in adults (18 years or older) who have failed or were intolerant to treatment with immunomodulators or corticosteroids but never failed treatment with a tumor necrosis factor (TNF) blocker, or who failed or were intolerant to treatment with one or more TNF blockers. Stelara is the first biologic therapy for Crohn's disease targeting interleukin (IL)-12 and IL-23 cytokines, which play a key role in inflammatory and immune responses. "Crohn's disease is a complex condition to treat, and not all therapies work for every patient," said William J. Sandborn, MD, Chief, Division of Gastroenterology, and Professor of Medicine, UC San Diego School of Medicine, and ... Read more

Related support groups: Crohn's Disease, Stelara, Ustekinumab

Stelara (ustekinumab) Receives FDA Approval to Treat Active Psoriatic Arthritis

Posted 23 Sep 2013 by Drugs.com

HORSHAM, Pa., Sept. 23, 2013 /PRNewswire/ – Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved Stelara (ustekinumab) alone or in combination with methotrexate for the treatment of adult patients (18 years or older) with active psoriatic arthritis. It is estimated that more than two million people in the U.S. are living with psoriatic arthritis1, a chronic autoimmune disease characterized by both joint inflammation and psoriasis skin lesions. "It is critical for dermatologists and rheumatologists to be able to offer new and novel treatment options to our adult patients living with psoriatic arthritis, a disease where additional biologic options are very much needed," said investigator and Steering Committee member Alice B. Gottlieb, triple board certified in dermatology, rheumatology and internal medicine, M.D., Ph.D, Chief and ... Read more

Related support groups: Psoriatic Arthritis, Stelara, Ustekinumab

Psoriasis Drug May Help People With Crohn's Disease: Study

Posted 17 Oct 2012 by Drugs.com

WEDNESDAY, Oct. 17 – The drug Stelara, used to treat the skin condition psoriasis, may also be effective against Crohn's disease, according to a new study. Researchers from the University of California, San Diego School of Medicine found Stelara (ustekinumab) blocks two proteins known to cause inflammation. Crohn's disease patients with moderate-to-severe cases of the debilitating inflammatory bowel disease experienced improvements after six weeks of treatment, the team noted. One specialist not connected to the study welcomed the results. "This study confirms an earlier study showing that ustekinumab can be an effective therapy," said Dr. Bruce Sands, professor of medicine at the Mount Sinai School of Medicine in New York City. "Given the large unmet need for these individuals with refractory [hard-to-treat] Crohn's disease, these results are a great step forward," he said. Roughly ... Read more

Related support groups: Psoriasis, Crohn's Disease, Stelara, Ustekinumab

Ask a Question

Further Information

Related Condition Support Groups

Crohn's Disease, Psoriatic Arthritis, Psoriasis

Related Drug Support Groups

Stelara

Ustekinumab Patient Information at Drugs.com